GSK plc (NYSE:GSK) Announces Dividend Increase - $0.39 Per Share

GSK plc (NYSE:GSK) announced a quarterly dividend on February 6th. Shareholders who are on record as of February 21st will receive a dividend of $0.3932 per share. This payment will be issued on April 10th. The new dividend reflects an annualized amount of $1.57, offering a yield of 4.32%. The ex-dividend date is also set for February 21st. This marks an increase from GSK's earlier quarterly dividend of $0.39.

Over the past three years, GSK has experienced an average annual decrease in its dividend of 17.2%. The company's payout ratio stands at 34.4%, indicating that its dividend payments are well-supported by its earnings. Analysts anticipate GSK will earn $4.07 per share in the coming year, suggesting that it will continue to manage its dividend payments effectively with a projected future payout ratio of 38.3%.

GSK Stock Performance

On the trading day following the announcement, GSK's shares fell by $1.33, bringing the stock price to $36.38. A total of 7,166,526 shares changed hands, exceeding the average trading volume of 4,646,120 shares. GSK has a market capitalization of approximately $75.39 billion. Current financial ratios show a P/E ratio of 23.62, a PEG ratio of 1.38, and a beta of 0.64. Its balance sheet shows a current ratio of 0.81, a quick ratio of 0.53, and a debt-to-equity ratio of 0.98. In the last year, GSK's stock has seen a low of $31.72 and a high of $45.92. The 50-day moving average price is $34.17 and the 200-day moving average price is $37.60.

Earnings Overview

GSK recently reported its quarterly earnings on February 5th, showcasing an EPS of $0.59 for the quarter, surpassing analysts' expectations of $0.44 by $0.15. The company recorded a return on equity of 50.62% alongside a net margin of 7.97%. Projections indicate that GSK is expected to report an EPS of $3.92 for the current fiscal year.

Analyst Ratings

Several equity research analysts have provided updates on GSK's stock. Jefferies Financial Group recently downgraded GSK from a "buy" to a "hold" with a new price target of $39.50. Guggenheim also downgraded the stock from "buy" to "neutral". StockNews.com changed its rating from "strong-buy" to "buy", while Deutsche Bank reclassified GSK from "buy" to "hold". Currently, six analysts rate GSK as a hold, one analyst as a buy, and three give it a strong buy rating. As per MarketBeat data, GSK has a consensus rating of "Moderate Buy" with a price target averaging $43.25.

About GSK

GSK plc operates through its subsidiaries to engage in the research, development, and manufacture of vaccines, specialty medicines, and general medications aimed at preventing and treating diseases. The company functions with two primary segments: Commercial Operations and Total R&D.

GSK, dividend, stocks